- Novel Coronavirus
-
Drug Discovery Services
- Antiviral Drug Discovery
- Complement Therapy
- SARS-CoV-2 Aptamers
- Antisense Oligonucleotides
- Protease Inhibitors
- Inhibitor of Host Cell Protease
- Abelson Kinase Inhibitors
- RNA Synthesis Inhibitors
- Nucleoside Analogue
- Neuraminidase Inhibitors
- Neutralizing Antibody
- Antiviral Peptide
- Broad-spectrum Antiviral Drug
- Anti-Inflammatory Drugs
- High-Throughput Screening
- Vaccine Discovery
- Evaluation Platforms for SARS-CoV-2 Drugs
- Antiviral Drug Discovery
- IVD Immunoassays
- Products
- Resources
- About Us
New Products for SARS-CoV-2 Omicron Variant (B.1.1.529)
Research into COVID-19 diagnostics, treatments and vaccines, especially Omicron relevant study, will continue to dominate the 2022 innovation. Creative Biolabs perseveres to seek tools to assist this work.
SARS-CoV-2 CPE Assay
Various pathological cell alterations triggered by eukaryotic viruses are referred to as the Cytopathic Effect (CPE). By CPE, viral proliferation could be estimated through observable changes in cultured cells under a light microscope. Creative Biolabs now provides top-rated antiviral assay services based on cytopathic effect (CPE) to help you screen potentially antiviral compounds.
SARS-CoV-2 Spike-pseudovirus Based Neutralization Assay Services
Creative Biolabs uses HIV-1 containing a luciferase reporter gene as a backbone plasmid, and co-transfects 293 cells with a plasmid expressing the SARS-CoV-2 spike protein to package a spike-pseudovirus with SARS-CoV-2 spike protein expressing on its surface and containing luciferase reporter gene inside. In combination with our proprietary ACE2-overexpressing cells, Creative Biolabs now provides neutralization assay services for our customers.
Protease Inhibitor Assay of SARS-CoV-2
The main protease of SARS-CoV-2 is considered to be essential for viral replication, and therefore is considered a promising target for COVID-19 antiviral therapy. To find and validate potent inhibitors for SARS-CoV-2 protease, Creative Biolabs provides protease assay service to help speed up the development of therapeutics to conquer COVID-19.
SARS-CoV-2 Virus-like Particles (VLPs)
Creative Biolabs has developed the SARS-CoV-2 VLP successfully and now offers high-quality VLP production services for our worldwide customers.
SARS-CoV-2 Aptamers
Working around the clock, we have developed a series of aptamers with high affinity for SARS-CoV-2 spike protein S1 and N protein and ensure that they can bind to the target protein in SPR detection. Contact us to find more information and explore how aptamers can help in your research.
Meet Us at the Upcoming Events
Creative Biolabs is proud to exhibit and participate in industry conferences where our scientists showcase innovative drug discovery solutions. Whether you are diving into scientific research, biopharmaceutical discovery and development, or industrial manufacturing, we strongly encourage you to come and meet us at our coming conferences! Our experts are excited to meet with our clients in person to discuss how we can assist in the development and optimization of your new drug discovery.